Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

I think it may be older news but this is (for us) the best part and bears repeating: "Also on Thursday, Nicola Mason, B.Vet.Med, PhD, DACVIM, of the University of Pennsylvania, School of Veterinary Medicine, presented preliminary research based on her clinical work with the osteosarcoma vaccine immunotherapy candidate. This novel HER2/neu-directed cancer immunotherapy (AT-014, ADXS-cHER2) is licensed by Aratana exclusively from Advaxis, Inc. The preliminary results from this study suggest that AT-014 is able to delay or prevent metastatic disease and prolong overall survival in dogs with osteosarcoma that had minimal residual disease following amputation and chemotherapy. Median survival in control dogs was 316 days (n = 13), and at the time of Dr. Mason’s presentation, the median survival in treated dogs had not yet been reached, with 80% of the dogs that received the complete vaccine series remaining alive (n = 15). Dr. Mason is conducting a second study evaluating combination therapy with AT-014 immunotherapy and radiation for dogs with primary osteosarcoma that cannot undergo amputation."